RU2416413C1 - Medication for treating blood loss ("spaskrov") - Google Patents

Abstract

FIELD: medicine.

SUBSTANCE: claimed is medication for treatment of blood loss, consisting of complex representing combination of insulin 14 U, glucose solution 10% - 400 ml, sodium adenosine triphosphate 1% - 1 ml, panangin 10 ml, strophanthin acetate 0.05% - 0.25 ml, ascorbic acid 5% - 2 ml, riboxin 10ml, analgin 25% - 1 ml, polyglucinum 6% -400 ml.

EFFECT: medication in express-mode simultaneously produces rehabilitating action on all factors of blood loss etiopathogenesis, including elimination of acidosis, stress and pain syndrome.

1 ex

Description

The invention relates to medicine, namely to means for the treatment of blood loss - blood substitutes.

Known funds for the treatment of blood loss - plasma substituting solutions (see M.D. Mashkovsky, "Medicines", M., 2008, pp. 673-677, 678-680, 681-684, "Big Medical Encyclopedia", M., 1980, volume 12, p. 48, 80; I.A. Kassirsky, G.A. Alekseev ", Clinical hematology", M., 1970, - p. 155-156, 158).

A disadvantage of these known agents is that they are limited only by the function of maintaining blood flow. Perftoran is contraindicated in hemophilia, allergic diseases, it is necessary to freeze during storage and transportation.

With large blood loss, blood, erythrocyte mass and plasma are transfused, which poses a risk of infection, including HIV, hepatitis, and an incompatibility reaction.

The objective of the present invention is to provide an effective tool for the accelerated treatment of blood loss - a blood substitute - due to the simultaneous exposure immediately to all factors of etiopathogenesis of blood loss.

The basis of the etiopathogenesis of blood loss is the following complex of factors combined among themselves:

- weakening of the gas transport function of the blood, namely, the transport of oxygen from red blood cells to tissues and the removal of CO ₂ (hypoxia),

- weakening of the output of red blood cells from the depot into the bloodstream, hematopoiesis, the differentiation of stem cells into cellular elements of the blood,

- weakening of insulin supply,

- weakening of immunity,

- violation of the rheology of blood and blood circulation,

- violation of carbohydrate, protein, lipid, mineral metabolism,

- violation of thermoregulation,

- impaired blood flow in the arteries of the brain and heart,

- impaired brain function, contractility of the heart,

- acidosis,

- pain syndrome,

- stress.

The essence of the claimed technical solution lies in the fact that for the treatment of blood loss, a drug is proposed - a substance that has a new previously unknown therapeutic quality, namely, unlike the prototype, it is capable of expressly performing a simultaneous rehabilitation effect on all factors of etiopathogenesis of blood loss:

- restoration and optimization of insulin supply,

- activation of the gas transport function of the blood - the transfer of oxygen from red blood cells to tissues and the output of CO ₂ ,

- the mobilization of red blood cells from the depot to the bloodstream, the activation of hematopoiesis, the differentiation of stem cells into the cellular elements of the blood, the strengthening of immunity,

- regulation of carbohydrate, protein, mineral lipid metabolism,

- improvement of blood rheology and blood circulation,

- improvement of coronary and cerebral circulation,

- improving brain function and contractility of the heart,

- elimination of acidosis,

- elimination of pain,

- elimination of stress.

The remedy for the treatment of blood loss (blood substitute) is characterized by a qualitatively and quantitatively complex combined composition and doses, allowing to carry out the treatment task in express mode. The complex composition of the funds:

Insulin 14 units.

Glucose solution 10% - 400 ml

Solution of sodium adenosine triphosphate 1% -1.0 ml

Pananginum solution 10 ml

A solution of strophanthin acetate 0.05% - 0.25 ml

A solution of ascorbic acid 10% - 2.0 ml

Riboxin solution 10 ml

Solution of dipyrone 25% - 1.0 ml

Polyglucin solution 6% - 400 ml

The drug uses compatible compounds authorized by the pharmaceutical committee in authorized doses (see M.D. Mashkovsky, “Medicines”, M. 2008, pp. 647, 533, 744, 709, 694, 159, 127, 745).

The product is sterile, administered intravenously drip. The volume and rate of administration are determined by the general condition of the patient, the level of blood pressure, and hematocrit.

The proposed tool for the treatment of blood loss - blood substitute - does not require freezing, convenient for use in emergency situations and field conditions.

Example

Patient B., 59 years old, was admitted to the surgical department on 05/03/2008 by an ambulance complaining of severe weakness, loose black stools, vomiting of the color of coffee grounds, dizziness, palpitations, feeling of cold in the body.

A health condition has developed in the last 3 days after alcohol abuse.

A history of chronic alcoholism, cirrhosis, varicose veins of the esophagus, atherosclerotic cardiosclerosis, myocardial dystrophy.

During transportation by ambulance, injections of vicasol with 2 ml were made intramuscularly, intravenously a solution of calcium chloride 10% -10 ml, intravenous drip solution of aminocaproic acid 100 ml.

Objectively: the condition is serious, pale, answers questions slowly. The pulse is 110 rpm, rhythmic. AD 90/60, t - 36 ° C. Above the lungs, percussion clear pulmonary sound, vesicular breathing. The heart is percussion, the borders are normal, the tones are muffled, the abdomen is soft, painful in the right hypochondrium in the region of the liver, which is 5 cm below the costal arch, is dense. The tongue is dry with a yellow coating.

Upon admission to the general blood test: red blood cells 1.6, hemoglobin - 61; col. pok. - 1.14; hematocrit - 12.6; lake. - 27000; P - 9; sigma - 88; lymph - 3; soe - 48.

Total urinalysis: beats. weight - 1012; protein - traces; units white blood cells.

Biochemical blood test: cholesterol - 8; creatinine - 63; urea - 9.7; direct bilirubin 17.1; indirect 58.6; sugar - 7.8; AlAT - 68; AsAT - 86. Blood type 01 Rh positive. ECG sinus rhythm, diffuse changes in the myocardium.

Taking into account gastrointestinal bleeding and anemia, a transfusion of canned blood was planned, which did not take place due to the presence of a blood and blood donor and patient incompatibility reaction during the test. An agent consisting of:

Insulin 14 units.

Glucose solution 10% - 400 ml

A solution of sodium adenosine triphosphate 1% - 1.0 ml

Pananginum solution 10 ml

A solution of strophanthin acetate 0.05% - 0.25 ml

A solution of ascorbic acid 5% - 2.0 ml

Riboxin solution 10 ml

Solution of dipyrone 25% - 1.0 ml

Polyglucin solution 6% - 400 ml

After transfusion, the condition improved: weakness, pallor of the skin, coldness in the body, dizziness and palpitations decreased. Vomiting and black loose stools stopped. Pulse 100 rpm, AD 100/70. In the blood test 05/04/2008 red blood cells 2.5; hemoglobin 70; col. - 0.8; hematocrit 21.3; white blood cells 15.6; P - 2; sigma - 79; lymphocytes - 12; mon - 7; soe - 32. Common. an. urine: beats. weight - 1015, units white blood cells.

05/05/2008: pulse of 96 per minute. AD - 100/70.

The agent consisting of:

Insulin 14 units.

Glucose solution 10% - 400 ml

A solution of sodium adenosine triphosphate 1% - 1.0 ml

Pananginum solution 10 ml

A solution of strophanthin acetate 0.05% - 0.25 ml

A solution of ascorbic acid 5% - 2.0 ml

Riboxin solution 10 ml

Solution of dipyrone 25% - 1.0 ml

Polyglucin solution 6% - 400 ml

In a blood test dated 05/06/2008: red blood cells 2.8; hemoglobin 80; col. pok. - 0.86; hematocrit 21.3; white blood cells 10000; P - 2; sigma - 67; m. - 4; l - 25; e. - 2; soe - 28.

Total an. urine: beats. weight - 1017 units white blood cells.

In a blood test dated 05/15/2008: red blood cells 3.2; Hb - 108; Ht - 28.8; lake. - 8.8; P - 1; sigma - 90; lymph - 7; mon - one; soe - 22.

Biochemical an. blood: cholesterol - 7; sugar - 7.0; AsAT - 40; AlAT - 50; creatinine - 53; urea - 6.7.

05/16/2008: pulse - 84 in min; AD 110/75. Discharged from the surgical department to continue the treatment of cirrhosis by a therapist.

Claims (1)

The use of a complex combination of insulin 14 units, glucose solution 10% - 400 ml, sodium adenosine triphosphate 1% - 1 ml, panangin - 10 ml, strophanthin acetate 0.05% - 0.25 ml, ascorbic acid 5% - 2 ml, riboxin - 10 ml, analgin 25% - 1 ml, polyglucin 6% - 400 ml as a means for the treatment of blood loss.